Anticoagulants Market Size, Share, Growth and Forecast, 2025-2035

Oral agents and aging patients drive anticoagulant demand

The global anticoagulants market was valued at USD 27.88 billion in 2025 and is projected to increase from USD 29.12 billion in 2026 to USD 43.07 billion by 2035, registering a CAGR of 4.45% during 2026–2035. Demand comes from the growing number of older adults with atrial fibrillation, venous thromboembolism and heart disease who need long-term stroke and clot prevention. North America held the largest regional share, 45.0% in 2025, because branded apixaban and rivaroxaban still sell at high prices in the United States. Asia Pacific is the fastest-growing region at 5.90% a year as aging in China, Japan and South Korea widens the treated population. Medicare negotiated prices for Eliquis and Xarelto took effect in January 2026, which lowers the value of each prescription in the largest market. As a result, growth now depends more on volume and on new Factor XI inhibitors than on price increases.

Which medicines and buyers does this market count?

The market counts manufacturer sales of prescription medicines that prevent or treat blood clots in arteries and veins. It covers novel oral anticoagulants such as apixaban, rivaroxaban, edoxaban and dabigatran, vitamin K antagonists such as warfarin, injectable direct thrombin inhibitors, heparins and other agents such as fondaparinux. Hospitals, retail pharmacies and online pharmacies dispense these medicines to inpatients and to patients on long-term therapy at home.

The scope excludes antiplatelet medicines such as aspirin and clopidogrel, thrombolytics used to dissolve existing clots and reversal agents. Value is counted once at the manufacturer net selling price, so distributor and pharmacy margins are not added. Dabigatran is counted with the novel oral agents, so the direct thrombin inhibitor group covers injectable products such as argatroban and bivalirudin.

Novel oral agents dominate stroke prevention spending

Why do novel oral agents lead the drug categories?

Based on drug category, the market is categorized into novel oral anticoagulants, vitamin K antagonists, direct thrombin inhibitors, heparin and others. Novel oral anticoagulants led with 72.0% of 2025 value because apixaban, rivaroxaban and edoxaban need no routine blood monitoring and cause fewer brain bleeds than warfarin. The others group grows fastest at 7.45% a year as Factor XI inhibitors approach approval. Low molecular weight heparin remains the hospital standard for surgical prophylaxis and cancer-associated clots.

How do oral and injectable products divide the market?

Based on route of administration, the market is categorized into oral and injectable products. Oral products led with 78.0% of 2025 value because most patients with atrial fibrillation take tablets for years. Oral products also grow fastest at 4.56% a year as hospital patients switch to tablets at discharge. Injectable products, mainly enoxaparin and unfractionated heparin, serve surgery, dialysis and acute care, where fast onset and easy reversal matter most.

Why does atrial fibrillation account for most use?

Based on application, the market is categorized into atrial fibrillation or myocardial infarction, deep vein thrombosis, pulmonary embolism and others. Atrial fibrillation and myocardial infarction led with 55.0% of 2025 value because stroke prevention in atrial fibrillation requires lifelong therapy for most patients. This group also grows fastest at 4.67% a year as more older adults are screened and diagnosed. Deep vein thrombosis and pulmonary embolism usually need shorter courses of 3 to six months unless clots recur.

How do pharmacies share anticoagulant sales?

Based on distribution channel, the market is categorized into retail pharmacy, hospital pharmacy and online pharmacy. Retail pharmacy led with 58.0% of 2025 value because long-term oral therapy is refilled every month at community pharmacies. Online pharmacy grows fastest at 6.44% a year as mail-order benefits and direct-to-patient programs expand. Hospital pharmacies dispense heparins and injectable thrombin inhibitors for surgery, intensive care and dialysis.

Aging populations and atrial fibrillation lift demand

How does population aging lift anticoagulant demand?

Population aging is the strongest volume driver because the risk of atrial fibrillation and venous clots rises sharply after age 65. World Bank data show that people aged 65 and older made up 29.8% of the population in Japan and 17.9% in the United States in 2024. China reached 14.7% in the same year, from a far larger population base. As a result, the number of patients eligible for long-term stroke prevention rises in every major market through 2035.

Why does atrial fibrillation screening widen the treated pool?

Wider detection of atrial fibrillation adds patients because many cases cause no symptoms until a stroke occurs. Wearable rhythm monitors, smartwatch alerts and pulse checks in primary care now identify more patients earlier. Guidelines recommend oral anticoagulation for most patients with atrial fibrillation and added stroke risk factors, so each new diagnosis usually leads to a prescription that lasts for many years. Patients who cannot take long-term therapy may instead receive left atrial appendage closure and other atrial fibrillation devices.

Download Free Sample

How do surgery and cancer care support injectable demand?

Surgery and cancer care support injectable demand because hospitals give heparins to prevent clots after orthopedic, abdominal and cancer surgery. Patients with cancer face a much higher risk of venous thromboembolism, and many receive heparin or oral factor Xa inhibitors for several months. Abelacimab, which Novartis gained when it completed the acquisition of Anthos Therapeutics in April 2025, is in Phase 3 trials for cancer-associated thrombosis. As a result, hospital demand stays stable even as oral agents dominate outpatient care.

Why does generic entry expand access?

Generic entry expands access because lower prices let health systems switch more patients from warfarin to novel oral agents. Generic rivaroxaban is widely sold in Europe, and Indian manufacturers supply large volumes of oral agents to emerging economies. In March 2025, Lupin launched rivaroxaban 2.5 mg tablets in the United States after final FDA approval of its generic application. As a result, treated patient numbers rise faster than value in price-sensitive markets such as India, Brazil and Southeast Asia.

Generic entry and Factor XI research reshape treatment

How is the shift to lower factor Xa inhibitor prices unfolding?

The shift to lower prices for factor Xa inhibitors is spreading from Europe to the United States. Medicare negotiated prices for Eliquis and Xarelto took effect on Jan. 1, 2026, after CMS announced the results in August 2024. Discounts across the 10 negotiated drugs ranged from 38% to 79% off list prices, according to the agreements reached. These changes mean that value growth increasingly depends on prescription volume rather than on price.

Why is direct-to-patient pricing emerging?

Direct-to-patient pricing is an emerging channel because uninsured and high-deductible patients often pay list prices for branded blood thinners. In July 2025, Bristol Myers Squibb and Pfizer announced a program to sell Eliquis directly to cash-paying patients. KFF reported that the price was USD 346 a month, a 43% discount from the USD 606 list price. As a result, online and mail-order channels gain a larger role in branded anticoagulant sales.

Download Free Sample

Where do Factor XI inhibitors open new demand?

Factor XI inhibitors open a large opportunity because they aim to prevent clots with less bleeding than current agents. Bayer announced in November 2025 that asundexian met its primary efficacy and safety endpoints in the Phase III OCEANIC-STROKE study in secondary stroke prevention. The FDA accepted the asundexian application under priority review in May 2026, and Japan accepted a parallel filing. If approved, this class could reach patients who now avoid anticoagulants because of bleeding fears.

How can emerging markets add treated patients?

Emerging markets offer an opportunity because many patients with atrial fibrillation in Asia, Latin America and Africa still receive warfarin or no anticoagulant at all. Low-cost generic oral agents from Indian and Chinese manufacturers make guideline-based treatment affordable for public health systems. India had 7.1% of its population aged 65 and older in 2024, compared with 11.0% in Brazil, so aging there is at an earlier stage. As a result, volume growth in these countries can continue well beyond 2035.

Bleeding risk and price setting restrain value growth

Why does bleeding risk limit prescribing?

Bleeding risk remains the main clinical barrier because every anticoagulant that prevents clots also raises the chance of serious bleeding. Older patients with kidney disease, falls or prior bleeds are often under-treated, even when their stroke risk is high. Specific reversal agents now exist for dabigatran and factor Xa inhibitors, but they are costly and not stocked in every hospital. As a result, many eligible patients still receive no anticoagulant, which caps volume growth until safer agents arrive.

Why do patent expiries pressure originator revenue?

Patent expiries pressure originator revenue because the two leading brands, Eliquis and Xarelto, face generic competition across major markets within the forecast period. In the United States, broad generic apixaban entry is expected later this decade, after which prices are likely to fall sharply. Generic entry in Europe has already cut prices for rivaroxaban, and payers use tenders to capture savings. As a result, Bayer, Johnson & Johnson, Bristol Myers Squibb and Pfizer face falling revenue from their main brands.

How does government price setting limit revenue?

Government price setting limits revenue because public payers cover most of the older patients who take anticoagulants. Medicare negotiation lowers net prices for the two leading brands in the United States, while European systems use reference pricing and tenders. China relies on volume-based procurement for many generic medicines sold to public hospitals, which keeps prices low. In turn, manufacturers must rely on higher volumes and lower production costs to protect margins.

What supply risks affect heparin products?

Heparin products face supply risk because most crude heparin comes from pig intestines, and much of it is processed in China. Outbreaks of African swine fever have reduced pig herds at times, which tightened supply and raised the cost of crude heparin. The 2008 contamination crisis also led regulators to require stricter testing of heparin sources. These risks push hospitals and manufacturers to diversify suppliers and to explore bovine and synthetic heparin alternatives.

North America leads value while Asia adds older patients

Why does North America hold the largest share?

North America held 45.0% of 2025 value and grows at 3.90% a year, the slowest pace among regions as negotiated and generic prices spread. The United States is the largest single market because Eliquis and Xarelto still dominate prescriptions for atrial fibrillation and venous clots. Canada pays lower prices than the United States through provincial drug plans and national price reviews. As a result, the region keeps the largest share through 2035, although its lead narrows after generic apixaban enters the United States.

How do generics shape the European market?

Europe accounted for 27.0% of 2025 value and grows at 4.00% a year as generic factor Xa inhibitors lower prices. Germany, the United Kingdom, France, Italy and Spain account for most regional spending, and treatment rates for atrial fibrillation are high. Edoxaban from Daiichi Sankyo holds a stronger position in Europe than in the United States. In turn, volume keeps growing with aging populations, while value growth stays modest across the region.

Download Free Sample

Why is Asia Pacific the fastest-growing region?

Asia Pacific represented 19.0% of 2025 value and is the fastest-growing region at 5.90% a year. Japan has the oldest population among major economies, and edoxaban is widely prescribed there. China has a fast-aging population, and public hospital procurement has made generic oral agents widely available. India supplies low-cost generics at home and abroad, so the region adds more treated patients than any other region through 2035.

How is Latin America moving away from warfarin?

Latin America held 5.0% of 2025 value and grows at 5.10% a year as Brazil and Mexico widen access to novel oral agents. Public systems in the region still rely heavily on warfarin, which needs regular blood tests and dose changes. Private insurers increasingly cover branded and generic factor Xa inhibitors, so oral agents gain share each year.

Where is demand growing in the Middle East & Africa?

The Middle East & Africa accounted for 4.0% of 2025 value and grows at 5.30% a year from a small base. Gulf states buy most branded anticoagulants in the region through government programs and private insurance. In Africa, limited access to diagnosis and monitoring keeps anticoagulant use low relative to clinical need.

Download Free Sample

Launches, deals and trial results since 2024

Factor XI inhibitors and detection tools set the next phase

• Factor XI inhibitors such as asundexian, milvexian and abelacimab target a clotting factor that matters more for clot growth than for normal bleeding control.
• Reversal agents such as idarucizumab and andexanet alfa let clinicians stop anticoagulant effects quickly during bleeding or emergency surgery.
• Fixed-dose oral regimens remove the need for routine blood tests, which makes long-term therapy easier for older patients.
• Digital rhythm monitoring through smartwatches and skin patches finds silent atrial fibrillation earlier and brings more patients to treatment.
• Bovine and synthetic heparins could reduce dependence on pig-derived supply chains if regulators accept them for wider use.

Originator alliances face generics and new entrants

Competition centers on two originator alliances that control most branded sales of oral anticoagulants. Bristol Myers Squibb and Pfizer market Eliquis, while Bayer and Johnson & Johnson share Xarelto, with Bayer selling it outside the United States. Daiichi Sankyo sells edoxaban as Lixiana and Savaysa, and Boehringer Ingelheim markets dabigatran as Pradaxa. Sanofi, Aspen, Fresenius Kabi and Hikma compete in heparins and other injectable products, where supply reliability and hospital contracts matter more than brand. As patents expire, Indian and Chinese generic makers win tenders in Europe and emerging markets. Novartis, through abelacimab and Bayer, through asundexian, lead the race to bring Factor XI inhibitors to patients. As a result, the market is moving from a two-brand structure toward generic volume plus a new premium class.

Companies profiled and their roles in this market

Where value in blood thinners is moving next

Credence Research's view is that the market is moving from price-led to volume-led growth as Medicare negotiation and generic entry reset prices for the leading factor Xa inhibitors. The market still grows at 4.45% a year to 2035 because aging and better detection keep adding patients. Factor XI inhibitors are the main upside, since a safer class could reach patients now left untreated because of bleeding fears. Originators that secure Factor XI approvals and generic makers with low-cost scale are best placed, while holders of older brands face the sharpest revenue decline.

How the anticoagulant estimates were built

The report uses 2025 as the base year and forecasts values for 2026 to 2035 in current U.S. dollars. Market values come from the Credence Research model, which combines treated patient estimates, therapy duration and net prices by drug category and region. Regional, drug category, route, application and channel splits are Credence Research estimates. Inputs were drawn from World Bank population statistics, CMS and FDA notices, company press releases and annual reports, and public reimbursement documents. No primary interviews or surveys were used in this edition.

What the next decade holds for blood thinner demand

By 2035, the market is projected to reach USD 43.07 billion, with novel oral agents still accounting for most value. Generic apixaban and rivaroxaban will lower prices in the United States and Europe, while volume rises with aging in Asia and Latin America. Factor XI inhibitors are expected to reach patients in the late 2020s if regulators approve current filings, adding a premium class for secondary stroke prevention and high-bleeding-risk patients. Heparins will keep a steady hospital role, and online pharmacies will gain share as direct-to-patient programs expand.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.